Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
NCT04573049 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- September 1, 2020
- Completion date
- December 30, 2022
- Enrollment
- 124 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
aortic valve stenosis, cardiac event, effect of drug, heart failure, inotropic agents, safety issues, transcatheter aortic valve replacement